

1. [OPPI with NLSU organises panel discussion to mark World IP Day](#) – Express Pharma

In a panel discussion organized to mark the World IP Day, discussions were held on how a good policy environment can reward innovation and protect intellectual property rights. The broad conclusion of the day was that innovation in the bi-pharmaceutical industry requires a robust regulatory system that ensures drug quality and safety, a well-financed health system that provides timely patient access to novel therapies, and a policy environment that rewards innovation and protects intellectual property rights.

2. [India won't succumb to any pressure on IPR issues: Nirmala Sitharaman](#) – Economic Times

Developed countries want

India to amend its IPR norms particularly with regard to pharmaceuticals sector. Talking about the compliance with global norms, Commerce and Industry Minister, Nirmala Sitharaman said, "We are TRIPS compliant in every way. I think we move forward being consistently with the global expectations without yielding to any pressure from anywhere and I would like to state that India's legislative framework

3. [Ashok Lavasa named Expenditure Secretary](#) – Economic Times

Ashok Lavasa, has been appointed the new secretary, department of expenditure. IAS officer Jai Priye Prakash has been appointed as Secretary, Department of Pharmaceuticals. 14 prominent changes have been made at the secretary level on Tuesday by the Appointments Committee of Cabinet headed by the Prime Minister. Senior IAS officer Leena Nair, chairperson of Marine Products Exports Development Authority under the department of commerce will be the new secretary of the ministry of women and child development from May 30

4. [Global pharma growth to remain steady despite cost pressures: Moody's](#) – Economic Times

The global pharmaceutical industry will see annual earnings growth of 3%-4% over the next 12-18 months as solid underlying fundamentals mitigate the effect of the strong US dollar and increasing scrutiny of drug prices, said Moody's Investors Service. Companies focusing on cancer and other complex diseases will see higher earnings growth, and companies with greater

1. [OPPI with NLSU organises panel discussion to mark World IP Day](#) – Express Pharma
2. [India won't succumb to any pressure on IPR issues: Nirmala Sitharaman](#) – Economic Times
3. [Ashok Lavasa named Expenditure Secretary](#) – Economic Times
4. [Global pharma growth to remain steady despite cost pressures: Moody's](#) – Economic Times
5. [Talks with India over FTA require both sides having 'something meaningful' to discuss: EU](#) – Business Standard
6. [344 fixed dose combination drugs banned in March: Govt](#) – Business Standard
7. [263 pharma firms given notices last year for overcharging](#) – Business Standard
8. [Govt bets on Indian Railways for anti-tobacco campaign](#) – Mint
9. [Innovator's effort lies in convincing that the world is diminished without his innovation: Arvind Vishwanathan](#) – Times of India
10. [Innovators need to learn nuances of IPR, says CII](#) – The Hindu
11. [Over 1 million children under 5 die in India every year: Govt](#) – Times of India
12. [Nearly 7 crore cases of diabetes in India in 2015: Govt](#) – The Hindu
13. [US quality regulator flags generics](#) – Hindustan Times
14. [India has more than 200,000 pending patent applications](#) – Business Today

exposure to the US dollar and patent expiration might witness tepid growth. Companies like Bristol Myers Squibb, Merck BSE 1.20 % &Co who have launched the new class cancer drugs in the area of immuno-oncology are expected to post strong numbers.

Similar story in Business Standard - [‘Global pharma growth to remain steady in next 12-18 months’](#)

5. [Talks with India over FTA require both sides having ‘something meaningful’ to discuss: EU](#) – Business Standard

Daniel Rosario, spokesperson trade, director-general communication – European Commission is seen quoted “For the EU and the European Commission, India is and remains an important partner and also when it comes to the trade policy we were engaged for a long period of time with India in negotiations for a free trade agreement but unfortunately the process came to a standstill a few years ago and since 2013 there was no further movement in this process”.

Expressing disappointment and concern over the EU banning sale of around 700 pharmaceutical products clinically tested by GVK Biosciences, India had deferred the talks with the 28-member bloc in August last year.

6. [344 fixed dose combination drugs banned in March: Govt](#) – Business Standard

According to J P Nadda, Safety and efficacy issues relating to certain drugs which have been banned in some countries have been examined and some of these have been allowed for continued marketing with stipulated restrictions.

The manufacturers also needed to mention 'Advice for healthcare professionals' on their package which includes patients with active bladder cancer or with a history of bladder cancer, and those with uninvestigated haematuria, should not receive pioglitazone while prescribers should review the safety and efficacy of pioglitazone in individuals after 3-6 months of treatment.

7. [263 pharma firms given notices lasts year for overcharging](#) – Business Standard

The NPPA issued demand notices to 263 companies amounting to Rs.928.32 crore during the last fiscal, and recoveries effected are to the tune of Rs.12.68 crore. Whenever companies are found overcharging the consumer in respect to price of medicines, NPPA issues demand notices for recovery of overcharged amount along with interest thereon under various provisions of DPCO (Drugs Price Control Order) 1995 and DPCO 2013

8. [Govt bets on Indian Railways for anti-tobacco campaign](#) – Mint

The outdoor campaign will show images and messages highlighting the harmful effects of smokeless tobacco. The campaign has been conceptualised and executed by the global health experts’ organization Vital Strategies and will be featured across eight states—Maharashtra, Uttar Pradesh, Chhattisgarh, Odisha, Karnataka, Tamil Nadu, Delhi and Punjab.

9. [Innovator’s effort lies in convincing that the world is diminished without his innovation: Arvind Vishwanathan](#) – Times of India

For a startup to survive, innovation is a must. Along with innovation comes the need to protect it. And startups are beginning to see what intellectual property rights (IPR) and patent registration can do to business.

10. [Innovators need to learn nuances of IPR, says CII](#) – The Hindu

During an event organized by CII in Tiruchi, speakers deliberated on protection of innovations in the form of patents can help create a huge value out of ideas and drive the economy of the country to greater heights. The IP awareness presentation conducted by the patent scientists and patent engineers from DexPatent, was attended by students and faculty members from colleges in and around Tiruchi. The session gave an orientation to the students on the cost of patent filing and the schemes available in India, especially in Tamil Nadu for start-ups and the small entities for patent registrations

11. [Over 1 million children under 5 die in India every year: Govt](#) – Times of India  
Around 1.26 million children under five years of age die in India every year with prematurity and neonatal infections being the major causes accounting for almost 57% of the total deaths. In the post-neonatal period, pneumonia and diarrhoea are found to be the major reasons for under five mortality. Highlighting the need for vaccinations and institutional deliveries to reduce the neonatal as well as infant mortality, Nadda said the government has taken a decision to provide free vaccination of pneumococcal conjugate (PCV) to children.
12. [Nearly 7 crore cases of diabetes in India in 2015: Govt](#) – The Hindu  
As per the International Diabetes Federation (IDF), the estimated cases of diabetes in India in the age group of 20-70 years were 6.68 crore and 6.91 crore in 2014 and 2015 respectively. It has also been stated therein that the prevalence of diabetes has increased by 80 per cent among women in India between 1980 to 2014. central government is implementing National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) for interventions up to district level under the National Health Mission.
13. [US quality regulator flags generics](#) – Hindustan Times  
Affordable medicines manufactured in India are under attack again in the United States. But this time it's not the American health watchdog, Food and Drug Administration (US FDA), but the pharmaceutical standards body US Pharmacopeia (USP), which sets the quality levels of drugs imported into the US. USP believes that rising quality concerns over 'Made in India' medicines may allow other emerging drug manufacturers, including China to overtake India, which is the world's largest producer of generic medicines.
14. [India has more than 200,000 pending patent applications](#) – Business Today  
Indian patent office has set up four subject specific patent examination groups in its Delhi, Chennai, Kolkata and Mumbai branches to streamline and speed up the handling of patent applications. India had 237,671 patent applications pending before the four patent offices on April 1. While Delhi had the most (88,297) pending applications, Chennai followed with 78,405 pending patent applications. The patent offices have also introduced an e-register facility to share all information of patents including renewals, assignments and other legal status with the public